With so much attention on protein lately, you might wonder if you’re getting enough. Grocery store shelves are lined with protein-fortified breakfast cereals and snack foods, and cottage cheese ...

(PVLA), Tuesday announced the issuance of a new U.S. patent covering its lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel, for the treatment of microcystic lymphatic ...

Palvella Therapeutics has announced the issuance of a fifth patent for its lead product candidate, QTORIN™ rapamycin anhydrous gel, by the United States Patent and Trademark Office. This patent ...

QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic malformations in the U.S. WAYNE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ...

On the clinical trial front, teams are collaborating with researchers to test treatments such as Truvada, Maraviroc and low-dose Rapamycin — drugs that weren’t originally designed for long COVID but ...

And while some longevity enthusiasts are taking the drug rapamycin because studies have shown it helps animals live longer, it also weakens the immune system and hasn’t been proved to work in ...